The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_000152.5(GAA):c.1123C>T (p.Arg375Cys)

CA8815176

290225 (ClinVar)

Gene: GAA
Condition: glycogen storage disease II
Inheritance Mode: Autosomal recessive inheritance
UUID: 1b55986e-7cf8-4e67-b6e9-9a5b3073152c

HGVS expressions

NM_000152.5:c.1123C>T
NM_000152.5(GAA):c.1123C>T (p.Arg375Cys)
NC_000017.11:g.80108536C>T
CM000679.2:g.80108536C>T
NC_000017.10:g.78082335C>T
CM000679.1:g.78082335C>T
NC_000017.9:g.75696930C>T
NG_009822.1:g.11981C>T
ENST00000302262.8:c.1123C>T
ENST00000302262.7:c.1123C>T
ENST00000390015.7:c.1123C>T
NM_000152.3:c.1123C>T
NM_001079803.1:c.1123C>T
NM_001079804.1:c.1123C>T
NM_000152.4:c.1123C>T
NM_001079803.2:c.1123C>T
NM_001079804.2:c.1123C>T
NM_001079803.3:c.1123C>T
NM_001079804.3:c.1123C>T

Uncertain Significance

Met criteria codes 3
PM5_Supporting PM2_Supporting PP3
Not Met criteria codes 3
PS3 PP4 PM3

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Lysosomal Storage Disorders Variant Curation Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 2

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Lysosomal Diseases VCEP
The NM_000152.5:c.1123 C>T variant in GAA is a missense variant predicted to cause substitution of arginine by cysteine at amino acid 375 (p.Arg375Cys). This variant has been detected in six individuals with abnormal newborn screening. Six patients with this variant had documented GAA deficiency with activity in the affected range in muscle, cultured skin fibroblasts, leukocytes, lymphocytes, whole blood or dried blood spot. Of those individuals, 4 were compound heterozygous for the variant and a pathogenic variant (3 patients with c.-32-13T>G and with c.670C>T) and 3 of those were confirmed in trans by family testing (PMID: 36246652, internal laboratory). One individual was homozygous for the variant. However, all patients were detected through abnormal newborn screening and there is no evidence of symptoms or diagnosis of Pompe disease. Therefore PM3 and PP4 will not be applied. The highest population minor allele frequency in gnomAD v2.1.1 is 0.0001636 (5/30554 alleles) in the South Asian population, which is lower than the ClinGen Lysosomal Diseases VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). The computational predictor REVEL gives a score of 0.954 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). Another missense variant[ c.1124G>T p.Arg375Leu] (PMIDs: 24158270, 22081099) in the same codon has been classified as likely pathogenic for Pompe disease by the ClinGen Lysosomal Diseases VCEP (PM5_Supporting). Expression of the variant in HEK293 cells showed 11.7% GAA enzyme activity. However, this assay does not meet the requirements for use by the ClinGen Lysosomal Diseases VCEP because this percentage is above the cut off established by the assay (11%) to be considered deficient enzyme activity. There is a ClinVar entry for this variant (Variation ID: 290225, 1 star review status) with 2 submitters classifying the variant as likely pathogenic and 3 classifying the variant as a VUS. In summary, this variant meets the criteria to be classified as a variant of uncertain significance for Pompe disease based on the ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert panel (specifications Version 2.0): PM2_Supporting, PM5_Supporting, PP3. (Classification approved by the ClinGen Lysosomal Diseases VCEP on Oct. 3, 2023)
Met criteria codes
PM5_Supporting
Another missense variant[ c.1124G>T p.Arg375Leu] (PMIDs: 24158270, 22081099) in the same codon has been classified as likely pathogenic for Pompe disease by the ClinGen Lysosomal Diseases VCEP (PM5_Supporting).
PM2_Supporting
The highest population minor allele frequency in gnomAD v2.1.1 is 0.0001636 (5/30554 alleles) in the South Asian population, which is lower than the ClinGen Lysosomal Diseases VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting).
PP3
The computational predictor REVEL gives a score of 0.954 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3).
Not Met criteria codes
PS3
Expression of the variant in HEK293 cells showed 11.7% GAA enzyme activity. However, this assay does not meet the requirements for use by the ClinGen Lysosomal Diseases VCEP because this percentage is above the cut off established by the assay (11%) to be considered deficient enzyme activity.
PP4
Six patients with this variant had documented GAA deficiency with activity in the affected range in muscle, cultured skin fibroblasts, leukocytes, lymphocytes, whole blood or dried blood spot (PMID: 36246652, internal laboratory). However, all patients were detected through abnormal newborn screening and there was no evidence of symptoms or diagnosis of Pompe disease. Therefore PP4 will not be applied.
PM3
This variant has been detected in at least 6 individuals. Of those individuals, 4 were compound heterozygous for the variant and a pathogenic variant (3 patients with c.-32-13T>G and with c.670C>T) and 3 of those were confirmed in trans by family testing (PMID: 36246652, internal laboratory). One individual was homozygous for the variant. However, all patients were detected through abnormal newborn screening and there is no evidence of symptoms or diagnosis of Pompe disease. Therefore PM3 will not be applied.
Approved on: 2023-10-03
Published on: 2023-11-03
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.